A multicenter, single-arm phase 2 study of surufatinib plus toripalimab for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

Authors :: Ji, Dongmei
Song, Lijie
Cheng, Ying
Shen, Weina
Kuang, Muyu
Chen, Jiaying
Yang, Minjie
Cui, Hongxia
Zhou, Jinghong
Shi, Haiyan
Tan, Panfeng
Fan, Songhua
Shi, Michael
Su, Weiguo
Ji, Qinghai
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p6089-6089, 1p
Publication Year :: 2023

Full Text Access

Tools